Glenmark Pharmaceuticals Ltd stock is about 9% below its 52-week high of ₹2,297.90 seen on 11 March, amid better business recovery. Consolidated revenue in the December quarter (Q3FY26) increased 15% year-on-year to ₹3,901 crore, while Ebitda margin expanded to 22% from 18%, reflecting better operating efficiency and product mix.
